Navigation Links
PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
Date:11/29/2007

FRANKLIN, Mass., Nov. 29 /PRNewswire-FirstCall/ -- PLC Systems Inc. (Amex: PLC) today reported that it has discussed the results of its pilot safety study of the RenalGuard System(TM) and Therapy with the U.S. Food and Drug Administration. Based upon the positive safety data already collected in the pilot study and its discussions with FDA, PLC has stopped enrolling new patients in the pilot study and will submit a request to transition into a new pivotal trial protocol.

The pilot trial was originally designed as a safety study for up to 40 patients; PLC has successfully enrolled and treated 23 patients in the pilot study at five approved sites to date. The company concluded that finishing the total planned enrollment was now unnecessary based upon the initial review of safety data already obtained.

Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "We are very pleased with the successful early conclusion to our pilot safety trial. This enables us to move forward expeditiously with our planned pivotal trial for this innovative therapy. Our pivotal trial is expected to be a multi-center, randomized controlled study designed to demonstrate that RenalGuard is effective in reducing the incidence of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing cardiovascular imaging procedures. The results from this pivotal trial will be used to support the regulatory approval process needed to market RenalGuard as a CIN prevention device. We expect to enroll patients at up to 30 sites throughout the country in this trial."

He added, "With the number of cardiovascular imaging procedures expected to grow in the future and more patients being deemed at risk of CIN due to un
'/>"/>

SOURCE PLC Systems Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
2. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
3. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
4. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
5. Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
8. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
9. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...ata from three studies,evaluating associations bet...d the rate of blood transfusions, as well as the p...r erythropoiesis-stimulating agents (ESAs),in Medi...e presented at the,American Society of Clinical On... meeting will take place in Chicago from May 30 to...
(Date:5/16/2008)...ion of a Small Molecule with Dem...., May 16 /- Nektar,Therape...oday from a Phase 1,study of NKTR- 102, PEGylated ...activity in patients with refractory solid tumors....olecule PEGylation technology,produced an increase...
(Date:5/16/2008)...r Novel Approach to Blood ...wire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), an...el small,molecule therapeutics, announced today th...or Antagonist (DARA), showed statistically signifi... in patients with mild to,moderate hypertension. P...
(Date:5/15/2008)...- Eisai Corporation of North,America announced tod...out,compounds in the company,s oncology pipeline, ...h have been accepted for presentation at the,44th ... Oncology (ASCO),taking place in Chicago from May... on Eisai marketed products and,investigational co...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Hospital Launches Landmark Project in Emergency Medicine 9268 1Hospital Launches Landmark Project in Emergency Medicine 9268 2Hanger Orthopedic Group Inc Announces 2007 Year End Earnings Release Conference Call 9265 1Hanger Orthopedic Group Inc Announces 2007 Year End Earnings Release Conference Call 9265 2International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 1International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 2International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 3International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 4International Association of Fire Fighters 28IAFF 29 Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO Oximetry 2508 5Other highlights in the Jan 8 JNCI 9262 1Other highlights in the Jan 8 JNCI 9262 2Other highlights in the Jan 8 JNCI 9262 3Other highlights in the Jan 8 JNCI 9262 4
...- CombinatoRx,Incorporated (NASDAQ: CRXX) today a...ed to its immuno-inflammatory product,candidates, ...t,Rheumatism (EULAR) Annual Congress of Rheumatolo... CRx-102 , In a poster entitled "Inhibition of Mac...CRx-102, a Novel Synergistic Combination,Drug Cand...
...bjective Sleep,Measures, MINNEAPOLIS, June 13, 200...ults presented today at SLEEP 2007, the 21st annua...ieties (APSS),VEC-162, a balanced melatonin (MT1/...rmaceuticals Inc. , demonstrated improvements,in o...d maintenance,in a Phase III trial of transient in...
Other Medicine Technology:Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 2Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 3Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 4Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 2Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 3Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo 4
(Date:5/16/2008)...ntry needs is more unemployed politicians - and ec...tCall/ -- Although nearly all,voters place health ...ist,a looming federal budgetary crunch means none...urrent presidential candidates is likely to become...y Leader Bill Frist., Jousting with Princeton Uni...
(Date:5/16/2008)...year-old Chinese students learn the lesson of help...uan earthquake, NANJING, China, May 16 /PRNewswir...earthquake, even the youngest members of China are...ef efforts. All around the,country, schools are ru...Led by the school,s principal, Ms. Zhang Lijun, th...
(Date:5/16/2008)...May 16 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Na...he treatment of cardiac,arrhythmias, announced tod...oCor common stock filed a complaint in the Superio...Diego, naming as defendants each member of the,Boa...entific Corporation.,The complaint is styled Secon...
(Date:5/16/2008)...Y., May 16 /PRNewswire-USNewswire/ -- Karin Weisbu...he nonprofit publisher of,Consumer Reports magazin...of the Year at CU,s Yonkers headquarters today., ...d. She bundles up in,the winter and rides in shirt...akes her along Quaker Ridge in New Rochelle, down ...
Breaking Medicine News(10 mins):Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Chinese Preschoolers Participate in Fund Drive to Help the Victims of Sichuan Quake 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 2Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 3
...und a new cheek cell analysis which detects early ... inexpensive and early screening method for detect...cancer using buccal mucosa or cells scraped from t...rmation that separates patients with lung cancer f...
...s more likely to occur in patients who take high d...afety profile of non-steroidal anti-inflammatory d...bserved as early as three days after starting an i...ered to have one of the most favorable safety prof...
...the illnesses affecting man was generally known. I...versely affect sex life and the sperm quality in h...ntists led by Biochemist Koonakapalyam Ramasami Mu...onic alcoholism decreases the level of testosteron...
... country has strictly prohibited the import of chi...Myanmar to combat the ongoing was against Bird flu...tional border with Myanmar and there is frequently...order. Mr. C Sangnghina, The Director of State Ani...
Other Medicine News:Health News:Early Lung cancer detected by studying Cheek Cells 2
Pre-Loaded with a Stylet., ,Available Cuffed or Uncuffed, pre-loaded with a stylet to facilitate quick intubations.
Worlds 1st spray on medical gel lubricant, Sprayglyde was specifically designed to assist the insertion of laryngeal masks.
Pediatric Tracheal Tubes with Micro-thin-walled cuffs.
Indications For Usage: , Emergency use. , When medicant during ventilation is required.
Medicine Products: